Synthetic THC (cannabinoid) drug developer MIRA Pharmaceuticals (MIRA) raised $8.93 million on Wednesday night (Aug. 2, 2023) by pricing its tiny IPO in sync with the terms in its prospectus: 1.28 million shares (1,275,000 shares) at $7.00. The stock opened flat at $7.00 at 10:45 a.m. EDT today (Thursday, Aug. 3, 2023) in its NASDAQ debut. By 1:06 p.m. EDT today, MIRA Pharmaceuticals’ stock was trading at $7.65, up about 9.3 percent. Shares of MIRA Pharmaceuticals closed today at $7.42, up 42 cents for a gain of 6.0 percent in their first day of NASDAQ trading.
Kingswood Investments, a division of Kingswood Capital Markets, was the sole book-runner.
MIRA Pharmaceuticals, based in Baltimore, is developing MIRA1a, a molecular synthetic THC (cannabinoid) drug to treat anxiety and cognitive decline typically associated with dementia. The company, incorporated in Florida, was formerly known as MIRA1A Therapeutics, according to the prospectus.
On Nov. 28, 2022, the U.S. Drug Enforcement Agency (DEA) confirmed in writing that it conducted a scientific review of the chemical structure of MIRA1a in accordance with the definitions within the CSA (the Controlled Substances Act) and its implementing regulations and determined that MIRA1a is not a controlled substance or listed chemical, the prospectus says.
MIRA Pharmaceuticals’ financial picture is typical for a preclinical biotech company – a net loss on no revenue for the last 12 months.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on IPOScoop.com’s website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.
